Quinolinic Acid

When your body is under sustained inflammation, immune activation, or metabolic stress, your cells shunt the amino acid tryptophan down a chemical pathway that ends with a small but biologically active molecule called quinolinic acid. Some of it spills into urine, where it can be measured non-invasively. The result is a window into a process that routine blood work does not capture.

This test is not a diagnosis. It is a signal of how hard your body's tryptophan-to-NAD+ machinery is working, and how much of that work is tilting toward the inflammatory, excitatory end of the spectrum. Across dozens of human studies, urinary quinolinic acid tends to rise in people who are sick, stressed, or carrying chronic immune activation, and to track with severity in several conditions.

What This Marker Actually Reflects

Quinolinic acid is a downstream product of the kynurenine pathway, the main route your body uses to break down tryptophan when inflammation is present. Immune cells such as macrophages and microglia (immune cells in the brain) ramp this pathway up in response to immune signals, producing more quinolinic acid relative to its more protective sibling metabolites. The end product of this pathway is NAD+, a molecule cells use to generate energy, so quinolinic acid sits at the intersection of inflammation, neurochemistry, and energy metabolism.

Because urinary quinolinic acid generally reflects peripheral (outside the brain) tryptophan handling, it captures whole-body pathway activity rather than a specific organ. A systematic review of 57 human studies found that urinary quinolinic acid is usually higher in patients than in healthy controls across a wide range of conditions, including cancers, infections, autoimmune disease, metabolic syndrome, psychiatric and neurodevelopmental disorders, and critical illness. That breadth is the point: this is a sensitivity marker, not a specificity marker.

Brain quinolinic acid cannot be inferred directly from a urine measurement. Patterns and ratios, such as quinolinic acid relative to tryptophan or to neuroprotective metabolites like kynurenic and picolinic acid, often carry more information than the absolute number alone.

Kidney Stress and Acute Injury

The clearest outcome data on urinary quinolinic acid come from kidney injury. In a study of 1,948 participants, the urinary quinolinic acid-to-tryptophan ratio (uQ:T) rose in pediatric acute kidney injury, and people in higher tertiles of this ratio had greater odds of developing acute kidney injury. A lower urinary quinolinic acid relative to its upstream precursor 3-hydroxyanthranilic acid may reflect reduced flux through the de novo NAD+ synthesis pathway in kidney tubule cells, which appears to make the kidney more vulnerable to acute injury under stress.

What this means for you: if you are heading into a major medical stressor such as cardiovascular surgery, sepsis, or any setting with high acute kidney injury risk, the kynurenine pathway pattern in your urine reflects how well your kidneys are likely to handle that stress. This is research-level information, not a clinical cutpoint, but it is one of the strongest signals we have for this marker.

Inflammation and Autoimmune Disease

Quinolinic acid is produced by activated immune cells, so it tends to rise where chronic immune activation lives. In a study of 741 participants with rheumatoid arthritis, alterations in tryptophan metabolism including elevated quinolinic acid were tied to disease severity. In systemic lupus erythematosus, a study of 148 people found that elevated serum kynurenine-to-tryptophan and quinolinic acid ratios were associated with worse cognitive test performance and more depression symptoms. These studies measured blood (not urine) quinolinic acid, so the urinary signal in autoimmune disease is best understood as a related but not identical readout.

If you carry a known autoimmune diagnosis, urinary quinolinic acid offers a complementary read on how much active inflammatory drive your body is processing through the kynurenine pathway, separate from disease-specific antibodies or sedimentation rate. It is best interpreted as a trend over time alongside your existing inflammatory markers.

Brain, Mood, and Neurodevelopmental Conditions

Quinolinic acid acts on a brain receptor system (the NMDA receptor) and can be pro-oxidant and excitotoxic when chronically elevated. In a study of 60 young autistic children, urinary metabolomics showed increased urinary quinolinic acid alongside a shift toward neurotoxic over neuroprotective kynurenine metabolites. In a study of 81 people with first-episode schizophrenia, peripheral kynurenine pathway analysis showed a shift toward the more excitatory branch reflecting greater quinolinic acid flux.

Major depressive disorder, bipolar disorder, cluster and pediatric migraine, ADHD, and alcohol use disorder have all shown shifts in kynurenine pathway metabolites in human studies, though the evidence is strongest in plasma and cerebrospinal fluid rather than urine. A urinary read is best understood as a peripheral indicator of pathway activation that may parallel central nervous system biology, not a direct brain measurement.

Gut Health and Tryptophan Handling

The gut is a major site of tryptophan metabolism, and disrupted gut biology pushes quinolinic acid up. In a study of 60 people with depression and small intestinal bacterial overgrowth, urinary quinolinic acid and kynurenine were increased and related to symptom severity and mood scores. A study of 120 people with irritable bowel syndrome found that the constipation-predominant subtype showed increased kynurenine pathway activity, with urinary quinolinic acid linked to depression scores.

For people with persistent gut symptoms, especially when those symptoms travel together with low mood, fatigue, or brain fog, urinary quinolinic acid can help quantify whether the kynurenine pathway is part of the story.

Cancer and Critical Illness

In a pilot study of 53 people with non-small cell lung cancer receiving PD-1 inhibitors, higher plasma quinolinic acid was associated with poorer overall survival, likely reflecting both higher disease burden and T-cell suppression. In a study of 5,364 participants across the Lung Cancer Cohort Consortium, higher prediagnostic circulating quinolinic acid was associated with a 20 to 30 percent higher risk of lung cancer, particularly in current smokers. Across critically ill populations, higher urinary quinolinic acid has predicted worse outcomes including hospital mortality.

These findings are not screening tools for cancer in healthy people. They are reminders that quinolinic acid is part of a broader inflammatory and immunometabolic signal that becomes more relevant in high-risk contexts.

Why a Single Reading Is Not Enough

Quinolinic acid is a research and exploratory marker. There are no standardized clinical cutpoints, and assay methods, units, and normalization (to creatinine, tryptophan, or osmolality) differ between labs. A single value tells you where you are right now relative to a reference population, but the more useful information comes from how your number moves with sustained behavior change, treatment, or recovery from an acute illness.

Because the pathway is highly responsive to acute stressors, fasting, recent protein intake, and illness, treat any single reading as a snapshot. Get a baseline, retest in 3 to 6 months if you are actively changing diet, supplements, or treating an inflammatory condition, and at least annually thereafter to track your direction of travel. Pay attention to the ratio of quinolinic acid to tryptophan or to neuroprotective metabolites if your lab reports them, since these patterns are often more informative than absolute concentrations.

When Results Can Be Misleading

Several common factors can distort a single urinary quinolinic acid reading:

• Recent high-protein or high-tryptophan meals: acute tryptophan loading and high-protein diets increase urinary quinolinic acid excretion. A single reading after a heavy protein meal can look elevated without reflecting your usual biology.
• Prolonged fasting: in a study of 13 adults, fasting raised urinary quinolinic acid by about 50 percent while serum quinolinic acid dropped, because the pathway shifts toward urinary excretion under fasting stress.
• Acute illness, surgery, or critical care: quinolinic acid rises sharply during severe infection, sepsis, and the post-operative period. Wait at least several weeks after recovery before reading the result as your baseline.
• Phthalate exposure: in studies of 30 men and 126 women, urinary quinolinic acid tracked exposure to phthalates from sources such as personal care products and certain medications, so high background environmental exposure can confound the signal.

Reconciling Conflicting Findings

You may notice that some studies report higher quinolinic acid linked to worse outcomes while others, particularly a meta-analysis on dementia, found lower blood levels of several kynurenine pathway metabolites in Alzheimer's disease. This is not a contradiction so much as a reminder that quinolinic acid is a phenotype indicator of pathway activity, not a simple good-number or bad-number marker. Different diseases shift the pathway in different directions, and tissue and matrix differences (urine, blood, brain) further complicate the picture. Interpret your result in context, with attention to the pattern across related metabolites where available, not as a single score on a universal scale.

What to Do With an Unexpected Result

If your urinary quinolinic acid is meaningfully elevated, do not treat it as a diagnosis. The next steps depend on what else you are seeing. If you have markers of chronic inflammation (a high hs-CRP or ferritin), pair this with a broader inflammatory workup and a search for the source: gut imbalance, autoimmune activity, chronic infection, or environmental exposures. If you have kidney risk factors, consider checking eGFR and cystatin C alongside urinary albumin-to-creatinine ratio, since kynurenine pathway shifts are tied to acute kidney injury susceptibility.

If the elevation pairs with mood symptoms, fatigue, or cognitive complaints, the kynurenine pathway is one piece of an evaluation that should also include thyroid function, B vitamin status (particularly B6, which is a key helper molecule for these enzymes), and a careful look at sleep and gut health. A specialist familiar with metabolomic testing, a functional medicine physician, or, for kidney-related concerns, a nephrologist, is the right next conversation. The goal is to figure out what is driving the pathway, not to chase the number itself.